MAAST DIGITAL Unveils AI-Powered ERMA Evaluate™: A Revolutionary Platform Set to Transform the Traditional Medical, Legal and Regulatory Review Process for Life Science Companies [Yahoo! F...
Neurogene Inc. (NGNE)
Company Research
Source: Yahoo! Finance
solution is set to redefine the Medical, Legal, and Regulatory (MLR) review process by integrating advanced AI, cutting-edge project management tools, and seamless content creation capabilities into a comprehensive platform. As the regulatory landscape becomes more complex, ERMA Evaluate™ addresses the growing demand for faster, more efficient MLR workflows by automating review processes without compromising compliance or quality control. This solution is specifically tailored for life sciences companies and other highly regulated industries, enabling organizations to accelerate the delivery of promotional materials to market and generate additional content from approved projects. ERMA Evaluate™ will undergo extensive beta testing later this year with MAAST DIGITAL's long-standing pharmaceutical clients. By testing the solution with live clients and incorporating feedback from a skilled advisory team the revolutionary platform is poised for a successful launch. "ERMA Evaluate™ i
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Neurogene (NASDAQ:NGNE) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome [Yahoo! Finance]Yahoo! Finance
- Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett SyndromeBusiness Wire
- Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]Yahoo! Finance
NGNE
Earnings
- 11/13/25 - Beat
NGNE
Sec Filings
- 12/15/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 8-K
- NGNE's page on the SEC website